CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication

Novo Nordisk's Ozempic is set for a significant EU label expansion, with the European Medicines Agency's CHMP recommending approval for peripheral artery disease (PAD) based on positive STRIDE study outcomes, which could establish it as the broadest-labeled GLP-1 RA. The company expects European Commission approval within two months, while a U.S. FDA decision on the PAD indication is anticipated by Q4 2025. Concurrently, regulatory applications for NVO's oral semaglutide, Rybelsus, are under review in the U.S. and EU for major adverse cardiovascular event prevention, with decisions expected in H2 2025. These developments highlight semaglutide as a critical growth engine for Novo Nordisk, even as the company's shares have declined 18.9% year-to-date.

Analysis

Novo Nordisk (NVO) has achieved a significant regulatory milestone with the European Medicines Agency’s CHMP adopting a positive opinion for the label expansion of Ozempic to include peripheral artery disease (PAD). This recommendation, based on the phase IIIb STRIDE study, positions Ozempic to potentially become the GLP-1 RA drug with the broadest approved label following an anticipated European Commission approval within two months. This development strengthens the company's core semaglutide franchise, which is its primary growth engine and has secured a 33.3% global diabetes market share. Further reinforcing this strategy are pending regulatory reviews for Rybelsus (oral semaglutide) in the U.S. and EU for preventing major adverse cardiovascular events, with decisions expected in the second half of 2025. Despite these positive fundamental catalysts, NVO's stock has demonstrated a notable divergence from its operational progress, with shares declining 18.9% year-to-date, significantly underperforming the industry's 2.7% decline.

Key Decisions for Investors

• Investors should monitor the imminent European Commission decision on Ozempic's PAD indication, expected within two months, as a key near-term catalyst that could reinforce market leadership.
• The significant 18.9% year-to-date stock price decline, despite a series of positive clinical and regulatory developments, may present a compelling entry point for those with a bullish long-term view on the semaglutide franchise.
• Consider the multi-year pipeline of value-accretive events, including the U.S. FDA decision on Ozempic for PAD and global decisions on Rybelsus for cardiovascular risk reduction, both anticipated in 2025.
• The expansion of both Ozempic and Rybelsus into cardiovascular indications beyond diabetes is a key strategic differentiator that could solidify Novo Nordisk's competitive moat in the metabolic disease space.